Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	3	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	4	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	5	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	6	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	7	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS	8	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	9	NOV 26	MARPAT enhanced with FSORT command
NEWS	10	NOV 26	MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS	11	NOV 26	CHEMSAFE now available on STN Easy
NEWS	12	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	13	DEC 01	ChemPort single article sales feature unavailable
NEWS	14	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	15	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	16	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	17	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:49:01 ON 12 JAN 2009

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 14:49:13 ON 12 JAN 2009

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4
DICTIONARY FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10598116\10598116a.str



```
chain nodes :
7  8  27  28  29  30  31  32  33
ring nodes :
1  2  3  4  5  6  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25

chain bonds :
1-31  4-7  5-29  7-8  8-9  8-27  8-28  10-15  29-30  30-32  31-33
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-10  9-14  10-11  11-12  12-13  13-14  15-16  15-20
16-17  17-18  18-19  19-20  21-22  21-24  22-25  23-24  23-25
exact/norm bonds :
4-7  5-29  7-8  8-9  8-27  8-28  22-25  23-24  23-25  29-30
exact bonds :
1-31  10-15  21-22  21-24  30-32  31-33
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-10  9-14  10-11  11-12  12-13  13-14  15-16  15-20
16-17  17-18  18-19  19-20
isolated ring systems :
containing 1 : 9 : 15 : 21 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:CLASS  28:CLASS
29:CLASS  30:CLASS  31:CLASS  32:CLASS  33:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 14:49:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:49:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        9 TO ITERATE

100.0% PROCESSED        9 ITERATIONS                                9 ANSWERS
SEARCH TIME: 00.00.01
```

L3 9 SEA SSS FUL L1

=> d scan

L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-
MF C19 H16 N6 O4 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):8

L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridine-2,6-14C2-sulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-
MF C19 H16 N6 O4 S



L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-, compd. with 1-methyl-2-pyrrolidinone, ammonium salt (1:?:?)
MF C19 H16 N6 O4 S . x C5 H9 N O . H3 N

CM 1



CM 2



L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-, sodium salt (1:1)
MF C19 H16 N6 O4 S . Na



L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Carbamic acid, N-(3-methoxy-5-methyl-2-pyrazinyl)-N-[[2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinyl]sulfonyl]-, 2-methylpropyl ester
MF C24 H24 N6 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl-2,3,5,6-d4]-
MF C19 H12 D4 N6 O4 S



L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl-5-14C)phenyl]-
MF C19 H16 N6 O4 S



L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-, ammonium salt (1:1)
MF C19 H16 N6 O4 S . H3 N



● NH_3

L3 9 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-, compd. with 2-aminoethanol (1:1)
MF C19 H16 N6 O4 S . C2 H7 N O

CM 1



CM 2

$H_2N-CH_2-CH_2-OH$

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	186.36	186.58

FILE 'CAPLUS' ENTERED AT 14:50:12 ON 12 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Jan 2009 VOL 150 ISS 3
FILE LAST UPDATED: 11 Jan 2009 (20090111/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l3
L4          25 L3

=> s l3 and (pd<=20020220 or ad<=20040220 or prd<=20040220)
            25 L3
      22708281 PD<=20020220
                 (PD<=20020220)
       4827837 AD<=20040220
                 (AD<=20040220)
       4299459 PRD<=20040220
                 (PRD<=20040220)
L5           9 L3 AND (PD<=20020220 OR AD<=20040220 OR PRD<=20040220)

=> d l5 1-9 ibib hitstr

L5   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2005:962267  CAPLUS
DOCUMENT NUMBER:         143:248505
TITLE:                   Chemical process in preparation of
                         oxadiazolylphenylboronic acid used in preparation of
                         pyrazinyl oxadiazolyl pyridine sulfonamide endothelin
                         receptor
INVENTOR(S):             Butlin, Margaret Anne; Butlin, Roger John; Hogan,
                         Philip John; Meudt, Andreas
PATENT ASSIGNEE(S):      Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE:                  PCT Int. Appl., 19 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
```

WO 2005080403 A2 20050901 WO 2005-GB567 20050217 <--
WO 2005080403 A3 20051124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2005214138 A1 20050901 AU 2005-214138 20050217 <--
CA 2555554 A1 20050901 CA 2005-2555554 20050217 <--
EP 1718655 A2 20061108 EP 2005-708373 20050217 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU
CN 1922193 A 20070228 CN 2005-80005406 20050217 <--
BR 2005007847 A 20070710 BR 2005-7847 20050217 <--
JP 2007523906 T 20070823 JP 2006-553660 20050217 <--
IN 2006MN00938 A 20070420 IN 2006-MN938 20060808 <--
MX 2006PA09399 A 20061017 MX 2006-PA9399 20060817 <--
US 20080161565 A1 20080703 US 2006-598116 20060817 <--
NO 2006004012 A 20061106 NO 2006-4012 20060906 <--
KR 2006129483 A 20061215 KR 2006-719278 20060919 <--
PRIORITY APPLN. INFO.: GB 2004-3744 A 20040220 <--
WO 2005-GB567 W 20050217
OTHER SOURCE(S): CASREACT 143:248505; MARPAT 143:248505
IT 863332-44-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(chemical process in preparation of oxadiazolylphenylboronic acid used in preparation of pyrazinyl oxadiazolyl pyridine sulfonamide endothelin receptor)
RN 863332-44-9 CAPLUS
CN Carbamic acid, N-(3-methoxy-5-methyl-2-pyrazinyl)-N-[[2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinyl]sulfonyl]-, 2-methylpropyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:409543 CAPLUS
DOCUMENT NUMBER: 142:457053
TITLE: Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy
INVENTOR(S): Lacasse, Eric; McManus, Daniel
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005042558	A1	20050512	WO 2004-CA1902		20041029 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20050148535	A1	20050707	US 2004-975974		20041028 <--
CA 2542904	A1	20050512	CA 2004-2542904		20041029 <--
EP 1682565	A1	20060726	EP 2004-789809		20041029 <--
R: DE, FR, GB					
JP 2007510408	T	20070426	JP 2006-537024		20041029 <--
PRIORITY APPLN. INFO.:			US 2003-516192P	P	20031030 <--
			WO 2004-CA1902	W	20041029

IT 186497-07-4, ZD-4054
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)
RN 186497-07-4 CAPLUS
CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:409357 CAPLUS
DOCUMENT NUMBER: 142:457052
TITLE: Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent
INVENTOR(S): Lacasse, Eric; McManus, Daniel; Durkin, Jon P.
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042030	A1	20050512	WO 2004-CA1900	20041029 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050119217	A1	20050602	US 2004-975790	20041028 <--
AU 2004284855	A1	20050512	AU 2004-284855	20041029 <--
CA 2542884	A1	20050512	CA 2004-2542884	20041029 <--
EP 1691842	A1	20060823	EP 2004-789807	20041029 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015779	A	20061226	BR 2004-15779	20041029 <--
CN 1901939	A	20070124	CN 2004-80039601	20041029 <--
JP 2007509861	T	20070419	JP 2006-537023	20041029 <--
MX 2006PA04920	A	20070216	MX 2006-PA4920	20060502 <--
IN 2006MN00614	A	20070420	IN 2006-MN614	20060526 <--
NO 2006002420	A	20060731	NO 2006-2420	20060529 <--
KR 2006127393	A	20061212	KR 2006-710619	20060530 <--

PRIORITY APPLN. INFO.: US 2003-516263P P 20031030 <--
WO 2004-CA1900 W 20041029

IT 186497-07-4, ZD-4054
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with chemotherapeutic agent)
RN 186497-07-4 CAPLUS
CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:283298 CAPLUS
DOCUMENT NUMBER: 142:349042
TITLE: Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms
INVENTOR(S): Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027842	A2	20050331	WO 2004-US30368	20040916 <--
WO 2005027842	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273910	A1	20050331	AU 2004-273910	20040916 <--
CA 2538570	A1	20050331	CA 2004-2538570	20040916 <--
EP 1670477	A2	20060621	EP 2004-788798	20040916 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014568	A	20061107	BR 2004-14568	20040916 <--
CN 1878556	A	20061213	CN 2004-80033294	20040916 <--
JP 2007505914	T	20070315	JP 2006-527024	20040916 <--
MX 2006PA03066	A	20060620	MX 2006-PA3066	20060317 <--
NO 2006001325	A	20060606	NO 2006-1325	20060323 <--
KR 2007012618	A	20070126	KR 2006-707244	20060414 <--
PRIORITY APPLN. INFO.:			US 2003-504310P P	20030918 <--

WO 2004-US30368 W 20040916

OTHER SOURCE(S): MARPAT 142:349042

IT 186497-07-4, ZD-4054
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorpromazine compound-antiproliferative drug antitumor combination)

RN 186497-07-4 CAPLUS

CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)



L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:232622 CAPLUS

DOCUMENT NUMBER: 142:303627

TITLE: Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an LHRH analog and/or a bisphosphonate

INVENTOR(S): Gallagher, Neil

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023264	A1	20050317	WO 2004-GB3733	20040902 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004269956	A1	20050317	AU 2004-269956	20040902 <--
AU 2004269956	B2	20080417		
CA 2537096	A1	20050317	CA 2004-2537096	20040902 <--
EP 1663236	A1	20060607	EP 2004-768282	20040902 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004013974	A	20061031	BR 2004-13974		20040902 <--
CN 1878555	A	20061213	CN 2004-80032911		20040902 <--
JP 2007504265	T	20070301	JP 2006-525875		20040902 <--
US 20060287241	A1	20061221	US 2006-569583		20060223 <--
NO 2006001051	A	20060403	NO 2006-1051		20060303 <--
MX 2006PA02485	A	20060620	MX 2006-PA2485		20060303 <--
IN 2006DN01692	A	20070323	IN 2006-DN1692		20060328 <--
PRIORITY APPLN. INFO.:			GB 2003-20806	A	20030905 <--
			WO 2004-GB3733	W	20040902

IT 186497-07-4
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(antitumor combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulfonamide and an LHRH analog and/or a bisphosphonate)
RN 186497-07-4 CAPLUS
CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:354796 CAPLUS
DOCUMENT NUMBER: 140:368653
TITLE: Endothelin receptor antagonist-EGF receptor tyrosine kinase inhibitor combination for the treatment of cancer
INVENTOR(S): Boyle, Francis Thomas; Curwen, Jon Owen; Gallagher, Neil James; Hancox, Ursula Joy; Hughes, Andrew Mark; Johnstone, Donna; Taylor, Sian Tomiko; Tonge, David William
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004035057	A1	20040429	WO 2003-GB4347	20031007 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501959	A1	20040429	CA 2003-2501959	20031007 <--
AU 2003269259	A1	20040504	AU 2003-269259	20031007 <--
AU 2003269259	B2	20070315		
EP 1553950	A1	20050720	EP 2003-751038	20031007 <--
EP 1553950	B1	20070808		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015140	A	20050816	BR 2003-15140	20031007 <--
CN 1703224	A	20051130	CN 2003-80101310	20031007 <--
CN 100342853	C	20071017		
JP 2006510605	T	20060330	JP 2004-544431	20031007 <--
AT 369136	T	20070815	AT 2003-751038	20031007 <--
NZ 539137	A	20080131	NZ 2003-539137	20031007 <--
ES 2289316	T3	20080201	ES 2003-751038	20031007 <--
NO 2005001658	A	20050506	NO 2005-1658	20050404 <--
MX 2005PA03808	A	20050608	MX 2005-PA3808	20050408 <--
ZA 2005002874	A	20060222	ZA 2005-2874	20050408 <--
US 20060122180	A1	20060608	US 2005-530794	20050408 <--
HK 1078784	A1	20071109	HK 2005-110831	20051128 <--
PRIORITY APPLN. INFO.:			GB 2002-23854 A	20021012 <--
			WO 2003-GB4347 W	20031007 <--

IT 186497-07-4, ZD 4054
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin receptor antagonist-EGF receptor tyrosine kinase inhibitor combination for treatment of cancer)

RN 186497-07-4 CAPLUS

CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:331974 CAPLUS
DOCUMENT NUMBER: 140:332519
TITLE: 5-HT1B/1D receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
INVENTOR(S): Curwen, Jon Owen; Hughes, Andrew Mark; Johnstone, Donna; Morris, Clive Dylan
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032922	A1	20040422	WO 2003-GB4338	20031006 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003274307	A1	20040504	AU 2003-274307	20031006 <--
EP 1551395	A1	20050713	EP 2003-758297	20031006 <--
EP 1551395	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508933	T	20060316	JP 2004-542622	20031006 <--
AT 366572	T	20070815	AT 2003-758297	20031006 <--
ES 2287520	T3	20071216	ES 2003-758297	20031006 <--
US 20060009512	A1	20060112	US 2005-530232	20050404 <--
PRIORITY APPLN. INFO.:			GB 2002-23367 A	20021009 <--
			WO 2003-GB4338 W	20031006 <--

IT 186497-07-4, ZD 4054
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-HT1B/1D receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist)
RN 186497-07-4 CAPLUS
CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:182737 CAPLUS
DOCUMENT NUMBER: 140:210754
TITLE: Therapeutic use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulfonamide
INVENTOR(S): Tonge, David William; Taylor, Sian Tomiko; Boyle, Francis Thomas; Hughes, Andrew Mark; Johnstone, Donna; Ashford, Marianne Bernice; Barrass, Nigel Charles
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018044	A2	20040304	WO 2003-GB3653	20030820 <--
WO 2004018044	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2496476	A1	20040304	CA 2003-2496476	20030820 <--
AU 2003255835	A1	20040311	AU 2003-255835	20030820 <--
AU 2003255835	B2	20070405		
BR 2003013655	A	20050621	BR 2003-13655	20030820 <--
EP 1545710	A2	20050629	EP 2003-792501	20030820 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688365	A	20051026	CN 2003-824409	20030820 <--
NZ 538114	A	20080229	NZ 2003-538114	20030820 <--
RU 2340343	C2	20081210	RU 2005-108349	20030820 <--
JP 2004083590	A	20040318	JP 2003-299605	20030825 <--

JP 3663202	B2	20050622			
JP 2005097312	A	20050414	JP 2004-311829		20041027 <--
NO 2005000689	A	20050321	NO 2005-689		20050209 <--
MX 2005PA01862	A	20050603	MX 2005-PA1862		20050216 <--
US 20060094729	A1	20060504	US 2005-524963		20050218 <--
AU 2007203079	A1	20070719	AU 2007-203079		20070702 <--
IN 2007DN06057	A	20070831	IN 2007-DN6057		20070802 <--
PRIORITY APPLN. INFO.:			GB 2002-19660	A	20020823 <--
			AU 2003-255835	A3	20030820 <--
			WO 2003-GB3653	W	20030820 <--
			JP 2003-299605	A3	20030825 <--
			IN 2005-DN536	A3	20050211

IT 186497-07-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulfonamide)
RN 186497-07-4 CAPLUS
CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:132770 CAPLUS
DOCUMENT NUMBER: 126:144291
ORIGINAL REFERENCE NO.: 126:27885a,27888a
TITLE: N-pyrazinyl-2-phenyl-3-pyridinesulfonamides and analogs endothelin receptor antagonists
INVENTOR(S): Bradbury, Robert Hugh; Butlin, Roger John; James, Roger
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640681	A1	19961219	WO 1996-GB1295	19960603 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,				

LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN

CA 2219742	A1	19961219	CA 1996-2219742	19960603	<--
CA 2219742	C	20070116			
AU 9658403	A	19961230	AU 1996-58403	19960603	<--
AU 715041	B2	20000113			
EP 832082	A1	19980401	EP 1996-919941	19960603	<--
EP 832082	B1	20011121			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI

CN 1192739	A	19980909	CN 1996-196149	19960603	<--
CN 1097051	C	20021225			
BR 9608611	A	19990511	BR 1996-8611	19960603	<--
JP 11509175	T	19990817	JP 1997-500209	19960603	<--
JP 3193058	B2	20010730			
HU 9802300	A2	19991028	HU 1998-2300	19960603	<--
HU 9802300	A3	20020228			
NZ 308619	A	20000128	NZ 1996-308619	19960603	<--
RU 2172738	C2	20010827	RU 1998-100054	19960603	<--
AT 209200	T	20011215	AT 1996-919941	19960603	<--
SK 282338	B6	20020107	SK 1997-1680	19960603	<--
CZ 289387	B6	20020116	CZ 1997-3887	19960603	<--
PT 832082	T	20020429	PT 1996-919941	19960603	<--
IL 122464	A	20020523	IL 1996-122464	19960603	<--
ES 2168487	T3	20020616	ES 1996-919941	19960603	<--
PL 187897	B1	20041029	PL 1996-324660	19960603	<--
ZA 9604615	A	19961209	ZA 1996-4615	19960604	<--
US 5866568	A	19990202	US 1996-658969	19960604	<--
IN 1996DE01209	A	20050311	IN 1996-DE1209	19960604	<--
HR 960272	B1	20060630	HR 1996-272	19960606	<--
NO 9705700	A	19971205	NO 1997-5700	19971205	<--
NO 314503	B1	20030331			
HK 1005801	A1	20021220	HK 1998-105010	19980606	<--
US 6060475	A	20000509	US 1998-211483	19981214	<--
US 6258817	B1	20010710	US 2000-504364	20000215	<--

PRIORITY APPLN. INFO.:	GB 1995-11507	A	19950607	<--
	GB 1995-19666	A	19950927	<--
	WO 1996-GB1295	W	19960603	<--
	US 1996-658969	A3	19960604	<--
	US 1998-211483	A3	19981214	<--

OTHER SOURCE(S): MARPAT 126:144291

IT 186497-07-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of n-pyrazinyl-2-phenyl-3-pyridinesulfonamides and analogs endothelin receptor antagonists)

RN 186497-07-4 CAPLUS

CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	43.23	229.81

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:52:02 ON 12 JAN 2009